Selected research
Industry Research
Therapeutic Peptide Industry Research Report 2026
Market perspective
The global Therapeutic Peptide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Therapeutic Peptide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Therapeutic Peptide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Therapeutic Peptide include Takeda, Teva, Sanofi, Johnson and Johnson, Novartis, Novo Nordisk, Merck, Eli Lilly and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Therapeutic Peptide market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Peptide Market by Company
Takeda
Teva
Sanofi
Johnson and Johnson
Novartis
Novo Nordisk
Merck
Eli Lilly
AbbVie
AstraZeneca
Ipsen
Therapeutic Peptide Segment by Type
Oral
Injection
Other
Therapeutic Peptide Segment by Application
Central Nervous System
Metabolic Disorders
Cancer
Other
Therapeutic Peptide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Therapeutic Peptide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Therapeutic Peptide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
- Other
Applications
- Central Nervous System
- Metabolic Disorders
- Cancer
- Other
Companies covered
- Takeda
- Teva
- Sanofi
- Johnson and Johnson
- Novartis
- Novo Nordisk
- Merck
- Eli Lilly
- AbbVie
- AstraZeneca
- Ipsen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Therapeutic Peptide Market Size (2021-2032)
- 2.2.2 Global Therapeutic Peptide Sales (2021-2032)
- 2.2.3 Global Therapeutic Peptide Market Average Price (2021-2032)
- 2.3 Therapeutic Peptide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.3.4 Other
- 2.4 Therapeutic Peptide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Central Nervous System
- 2.4.3 Metabolic Disorders
- 2.4.4 Cancer
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Therapeutic Peptide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Therapeutic Peptide Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Therapeutic Peptide Revenue of Manufacturers (2021-2026)
- 3.4 Global Therapeutic Peptide Average Price by Manufacturers (2021-2026)
- 3.5 Global Therapeutic Peptide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Therapeutic Peptide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Therapeutic Peptide, Product Type & Application
- 3.8 Global Manufacturers of Therapeutic Peptide, Established Date
- 3.9 Global Therapeutic Peptide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Therapeutic Peptide Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Therapeutic Peptide Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Therapeutic Peptide Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Johnson and Johnson
- 4.4.1 Johnson and Johnson Company Information
- 4.4.2 Johnson and Johnson Business Overview
- 4.4.3 Johnson and Johnson Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson and Johnson Therapeutic Peptide Product Portfolio
- 4.4.5 Johnson and Johnson Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Therapeutic Peptide Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Novo Nordisk
- 4.6.1 Novo Nordisk Company Information
- 4.6.2 Novo Nordisk Business Overview
- 4.6.3 Novo Nordisk Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novo Nordisk Therapeutic Peptide Product Portfolio
- 4.6.5 Novo Nordisk Recent Developments
- 4.7 Merck
- 4.7.1 Merck Company Information
- 4.7.2 Merck Business Overview
- 4.7.3 Merck Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck Therapeutic Peptide Product Portfolio
- 4.7.5 Merck Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Therapeutic Peptide Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 AbbVie
- 4.9.1 AbbVie Company Information
- 4.9.2 AbbVie Business Overview
- 4.9.3 AbbVie Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AbbVie Therapeutic Peptide Product Portfolio
- 4.9.5 AbbVie Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Therapeutic Peptide Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 Ipsen
- 4.11.1 Ipsen Company Information
- 4.11.2 Ipsen Business Overview
- 4.11.3 Ipsen Therapeutic Peptide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ipsen Therapeutic Peptide Product Portfolio
- 4.11.5 Ipsen Recent Developments
5 Global Therapeutic Peptide Market Scenario by Region
- 5.1 Global Therapeutic Peptide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Therapeutic Peptide Sales by Region: 2021-2032
- 5.2.1 Global Therapeutic Peptide Sales by Region: 2021-2026
- 5.2.2 Global Therapeutic Peptide Sales by Region: 2027-2032
- 5.3 Global Therapeutic Peptide Revenue by Region: 2021-2032
- 5.3.1 Global Therapeutic Peptide Revenue by Region: 2021-2026
- 5.3.2 Global Therapeutic Peptide Revenue by Region: 2027-2032
- 5.4 North America Therapeutic Peptide Market Facts & Figures by Country
- 5.4.1 North America Therapeutic Peptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Therapeutic Peptide Sales by Country (2021-2032)
- 5.4.3 North America Therapeutic Peptide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Therapeutic Peptide Market Facts & Figures by Country
- 5.5.1 Europe Therapeutic Peptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Therapeutic Peptide Sales by Country (2021-2032)
- 5.5.3 Europe Therapeutic Peptide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Therapeutic Peptide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Therapeutic Peptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Therapeutic Peptide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Therapeutic Peptide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Therapeutic Peptide Market Facts & Figures by Country
- 5.7.1 South America Therapeutic Peptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Therapeutic Peptide Sales by Country (2021-2032)
- 5.7.3 South America Therapeutic Peptide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Therapeutic Peptide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Therapeutic Peptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Therapeutic Peptide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Therapeutic Peptide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Therapeutic Peptide Sales by Type (2021-2032)
- 6.1.1 Global Therapeutic Peptide Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Therapeutic Peptide Sales Market Share by Type (2021-2032)
- 6.2 Global Therapeutic Peptide Revenue by Type (2021-2032)
- 6.2.1 Global Therapeutic Peptide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Therapeutic Peptide Revenue Market Share by Type (2021-2032)
- 6.3 Global Therapeutic Peptide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Therapeutic Peptide Sales by Application (2021-2032)
- 7.1.1 Global Therapeutic Peptide Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Therapeutic Peptide Sales Market Share by Application (2021-2032)
- 7.2 Global Therapeutic Peptide Revenue by Application (2021-2032)
- 7.2.1 Global Therapeutic Peptide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Therapeutic Peptide Revenue Market Share by Application (2021-2032)
- 7.3 Global Therapeutic Peptide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Therapeutic Peptide Value Chain Analysis
- 8.1.1 Therapeutic Peptide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Therapeutic Peptide Production Mode & Process
- 8.2 Therapeutic Peptide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Therapeutic Peptide Distributors
- 8.2.3 Therapeutic Peptide Customers
9 Global Therapeutic Peptide Analyzing Market Dynamics
- 9.1 Therapeutic Peptide Industry Trends
- 9.2 Therapeutic Peptide Industry Drivers
- 9.3 Therapeutic Peptide Industry Opportunities and Challenges
- 9.4 Therapeutic Peptide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst